Factor Vila, recombinant

NovoSeven [TR assigned to Novo Nordisk A/S] Coagulation factor Vila (recombinant) [FDA] rFVIIa [SY]... 

Coagulation factor Vila recombinant (Novo-Seven )... 

NOVOSEVEN (Eptacog Novo Nordisk alfa) [BHK-expressed recombinant glycoprotein, coagulation factor Vila (recombinant) glycoprotein]... 

Recombinant factor Vila may be considered as an alternative to prothrombin complex concentrate... 

Recombinant factor Vila has been shown to have a benefit in the treatment of ICH. The Recombinant Activated Factor VII... 

Intracerebral Hemorrhage Trial compared three different doses and placebo. Doses were 40,80, or 160 mcg/kg or placebo given as an IV infusion over 1 to 2 minutes within 4 hours after the onset of symptoms. Hematoma growth was decreased at 24 hours, mortality was decreased at 90 days, and overall functioning was increased at 90 days. Further studies are ongoing to evaluate the role of recombinant factor Vila in ICH treatment.41... 

A recombinant form of factor Vila (called NovoSeven or eptacog alfa-activated ) is marketed by Novo-Nordisk (Table 12.2). The recombinant molecule is produced in a BHK cell line, and the final product differs only slightly (in its glycosylation pattern only) from the native molecule. 

Klausen, N. K., and Kornfelt, T. (1995). Analysis of the glycoforms of human recombinant factor Vila by capillary electrophoresis and high-performance liquid chromatography.. Chromatogr. A 718, 195-202. 

Monroe, D. M., Hoffman, M., Allen, G. A., and Roberts, H. R., The factor Vll latelet interplay Effectiveness of recombinant factor Vila in the treatment of bleeding in severe thrombocytopathia. 

Vlasuk GP, Bradbury A, Lopes-Kinninger L, Colon S, Bergum PW, Maki S, Rote WE. Pharmacokinetics and anticoagulant properties of the factor Vila - tissue factor inhibitor recombinant nematode anticoagulant protein c2 following subcutaneous administration in man dependence on the stoichiometric binding to circulating factor X. Thromb Haemost 2003 90 803-12. 

Hematologic and coagulation factors Coagulation factor Vila (human recombinant), produced in BHK cells NovoSeven Lyophilized 60 or 240 lU equivalent to 12 or 4.8 mg vial (does not contain albumin) Intravenous bolus... 

Coagulation factor Vila (human recombinant), produced in BHK cells... 

Human recombinant Factor Vila Complex tissue factor/factor Vila ligands designed to bind to the Gla-domain in Factor Vila. Solid-phase combinatorial chemistry solution-phase synthesis of a sub-library Affinity chromatography SPR 7,15 ... 

Lusher, J. M. (1996). Recombinant factor Vila (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. 

Schreiber MA. Preclinical trauma studies of recombinant factor Vila. Crit Care 2005 9 S25-8. 

In this assay, 100 nM recombinant soluble tissue factor and 2nM recombinant human factor Vila were added to a 96-well assay plate containing 0.4 mM of a selected experimental agent and V-methylsulfonyl-D-Phe-Gly-Arg-p-nitroaniline... 

For patients with high titre factor VIII inhibitors, standard factor IX complex products are first-line therapy but activated factor IX complex concentrates may be necessary for continued, more frequent or more severe bleeding. Porcine factor VIII or recombinant human factor Vila may be necessary for major bleeds or elective surgery. 

Inhibitor formation has been observed in only a few patients with factor XI deficiency. Like patients with hemophilia A and B, these patients may be treated with prothrombin complex concentrates or recombinant factor Vila (2). 

Ingerslev J. Efficacy and safety of recombinant factor Vila in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000 26(4) 425-32. 

---